MedTrace Logo

To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656

NCT01083212 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2010-07-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656

Conditions

Interventions

DRUG

AZD1656

Single dose,oral tablet

DRUG

Gemfibrozil

Oral tablet bid on day 1 - 5.

DRUG

Placebo

Oral tablet bid on day 1-5

Sponsors & Collaborators

Principal Investigators

  • Stanko Skrtic · AstraZeneca

  • Aslak Rautio · Quintiles Hermelinen AB

  • Wolfgang Kuhn · Quintiles AB

  • Folke Sjöberg · J.J. Berzelius Clinical Research Center AB

  • Mirjana Kujacic · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01083212 on ClinicalTrials.gov